IP Library › Patent Application 18539519
Patent Application
App. No. 18/539,519

SUBSTITUTED HETEROCYCLIC COMPOUNDS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/539,519
Abstract

There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.

Claims (16)

1 . A method of treating a disease, comprising administering to a patient in need of such treatment, a therapeutically-effective amount of a compound of the formula

or a stereoisomer or pharmaceutically acceptable salt thereof, wherein

X is —N— or —CH—;

R 1 is —C(O)R 1a ;

R 1a is C 3-6 cycloalkyl;

R 2 is C 1-6 alkoxy;

R 3 is C 1-6 alkyl or C 3-6 cycloalkyl,

wherein the disease is a neurodegenerative disease selected from Alzheimer's disease, Parkinson's disease, ALS or Multiple Sclerosis.

2 . A method of treating a disease, comprising administering to a patient in need of such treatment, a therapeutically-effective amount of a compound or a pharmaceutically acceptable salt thereof, selected from

N-(4-((3-methoxy-4-(2-methyl-2H-1,2,3-triazol-4-yl)pyridin-2-yl)amino)-5-propionylpyridin-2-yl)cyclopropanecarboxamide,

N-(4-((3-methoxy-4-(2-cyclopropyl-2H-1,2,3-triazol-4-yl)pyridin-2-yl)amino)-5-propionylpyridin-2-yl)cyclopropanecarboxamide,

N-(4-((2-methoxy-3-(2-methyl-2H-1,2,3-triazol-4-yl)phenyl)amino)-5-propionylpyridin-2-yl)cyclopropanecarboxamide,

N-(4-((4-fluoro-2-methoxy-3-(2-methyl-2H-1,2,3-triazol-4-yl)phenyl)amino)-5-propionylpyridin-2-yl)cyclopropanecarboxamide,

N-(4-((3-fluoro-2-methoxy-3-(2-methyl-2H-1,2,3-triazol-4-yl)phenyl)amino)-5-propionylpyridin-2-yl)cyclopropanecarboxamide, and

N-(4-((3-methyl-2-methoxy-3-(2-methyl-2H-1,2,3-triazol-4-yl)phenyl)amino)-5-propionylpyridin-2-yl)cyclopropanecarboxamide,

wherein the disease is a neurodegenerative disease selected from Alzheimer's disease, Parkinson's disease, ALS or Multiple Sclerosis.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2024
From: SPERGEL, STEVEN H.; MOSLIN, RYAN M.; MERTZMAN, MICHAEL EDWARD
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 066066/0284 →